HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated)

HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated)

rabies immunoglobulin

Manufacturer:

Grifols

Distributor:

Luen Cheong Hong
Full Prescribing Info
Contents
Immune globulin human rabies vaccine.
Description
HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated), rabies immune globulin (human), treated with solvent/detergent, is a sterile solution of antirabies immune globulin for IM administration; it contains no preservative. It is prepared by cold ethanol fractionation from the plasma of donors hyperimmunized with rabies vaccine. The immune globulin is isolated from solubilized Cohn Fraction II. The Fraction II solution is adjusted to a final concentration of 0.3% tri-n-butyl phosphate (TNBP) and 0.2% sodium cholate. After the addition of solvent (TNBP) and detergent (sodium cholate), the solution is heated to 30°C and maintained at that temperature for not less than 6 hrs. After the viral inactivation step, the reactants are removed by precipitation, filtration and finally, ultrafiltration and diafiltration. HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) is formulated as a 15-18% protein solution at a pH of 6.4-7.2 in 0.21-0.32 M glycine. It is then incubated in the final container for 21-28 days at 20-27°C. HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) is standardized against the US Standard Rabies Immune Globulin to contain an average potency value of 150 iu/mL. The US unit of potency is equivalent to the international unit (iu) for rabies antibody.
The 2-mL vial contains a total of 300 iu which is sufficient for a child weighing 15 kg. The 10-mL vial contains a total of 1500 iu which is sufficient for an adult weighing 75 kg.
The removal and inactivation of spiked model enveloped and non-enveloped viruses during the manufacturing process for HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) has been validated in laboratory studies. Human immunodeficiency virus, type 1 (HIV-1) was chosen as the relevant virus for blood products; bovine viral diarrhea virus (BVDV) was chosen to model hepatitis C virus; pseudorabies virus (PRV) was chosen to model hepatitis B virus and the herpes viruses; and reovirus type 3 (Reo) was chosen to model non-enveloped viruses and for its resistance to physical and chemical inactivation. Significant removal of model enveloped and non-enveloped viruses is achieved at 2 steps in the Cohn fractionation process leading to the collection of Cohn Fraction II: The precipitation and removal of Fraction III in the processing of Fraction II + IIIW suspension to Effluent III and the filtration step in the processing of Effluent III to Filtrate III. Significant inactivation of enveloped viruses is achieved at the time of treatment of solubilized Cohn Fraction II with TNBP/sodium cholate.
Action
Pharmacology: The usefulness of prophylactic rabies antibody in preventing rabies in humans when administered immediately after exposure was dramatically demonstrated in a group of persons bitten by a rabid wolf in Iran. Similarly, beneficial results were later reported from the USSR. Studies coordinated by WHO helped determine the optimal conditions under which antirabies serum of equine origin and rabies vaccine can be used in man. These studies showed that serum can interfere to a variable extent with the active immunity induced by the vaccine, but could be minimized by booster doses of vaccine after the end of the usual dosage series.
Preparation of rabies immune globulin of human origin with adequate potency was reported by Cabasso et al. In carefully controlled clinical studies, this globulin was used in conjunction with rabies vaccine of duck embryo origin (DEV). These studies determined that a human globulin dose of 20 iu/kg of rabies antibody, given simultaneously with the first DEV dose, resulted in amply detectable levels of passive rabies antibody 24 hrs after injection in all recipients. The injections produced minimal, if any, interference with the subject's endogenous antibody response to DEV.
More recently, human diploid cell rabies vaccines (HDCV) prepared from tissue culture fluids containing rabies virus have received substantial clinical evaluation in Europe and the United States. In a study in adult volunteers, the administration of rabies immune globulin (human) did not interfere with antibody formation induced by HDCV when given in a dose of 20 iu/kg body weight simultaneously with the 1st dose of vaccine.
In a clinical study in 8 healthy human adults receiving a 20-iu/kg IM dose of HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated), detectable passive rabies antibody titers were observed in the serum of all subjects by 24 hrs post-injection and persisted through the 21-day study period. These results are consistent with prior studies with non-solvent/detergent-treated product.
Indications/Uses
Rabies vaccine and HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should be given to all persons suspected of exposure to rabies with one exception: Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should be administered as promptly as possible after exposure, but can be administered up to the 8th day after the 1st dose of vaccine is given.
Recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the US Public Health Service Immunization Practices Advisory Committee (ACIP).
Every exposure to possible rabies infection must be individually evaluated. The following factors should be considered before specific antirabies treatment is initiated:
Species of Biting Animal: Carnivorous wild animals (especially skunks, foxes, coyotes, raccoons and bobcats) and bats are the animals most commonly infected with rabies and have caused most of the indigenous cases of human rabies in the United States since 1960. Unless the animal is tested and shown not to be rabid, post-exposure prophylaxis should be initiated upon bite or non-bite exposure to these animals (see Type of Exposure). If treatment has been initiated and subsequent testing in a competent laboratory shows the exposing animal is not rabid, treatment can be discontinued.
In the United States, the likelihood that a domestic dog or cat is infected with rabies varies from region to region; hence, the need for post-exposure prophylaxis also varies. However, in most of Asia and all of Africa and Latin America, the dog remains the major source of human exposure; exposures to dogs in such countries represent a special threat. Travelers to those countries should be aware that >50% of the rabies cases among humans in the United States result from exposure to dogs outside the United States.
Rodents (eg, squirrels, hamsters, guinea pigs, gerbils, chipmunks, rats and mice) and lagomorphs (including rabbits and hares) are rarely found to be infected with rabies and have not been known to cause human rabies in the United States. However, from 1971 through 1988, woodchucks accounted for 70% of the 179 cases of rabies among rodents reported to CDC. In these cases, the state or local health department should be consulted before a decision is made to initiate post-exposure antirabies prophylaxis.
Circumstances of Biting Incident: An unprovoked attack is more likely to mean that the animal is rabid. (Bites during attempts to feed or handle an apparently healthy animal may generally be regarded as provoked.)
Type of Exposure: Rabies is transmitted only when the virus is introduced into open cuts or wounds in skin or mucous membranes. If there has been no exposure, post-exposure treatment is not necessary. Thus, the likelihood that rabies infection will result from exposure to a rabid animal varies with the nature and extent of the exposure. Two categories of exposure should be considered:
Bite: Any penetration of the skin by teeth. Bites to the face and hands carry the highest risk, but the site of the bite should not influence the decision to begin treatment.
Bat-associated strains of rabies can be transmitted to humans either directly through a bat's bite or indirectly through the bite of an animal previously infected by a bat. Because some bat bites may be less severe, and therefore more difficult to recognize than bites inflicted by larger mammalian carnivores, rabies post-exposure treatment should be considered for any physical contact with bats when bite or mucous membrane contact cannot be excluded.
Non-Bite: Scratches, abrasions, open wounds or mucous membranes contaminated with saliva or any potentially infectious material eg, brain tissue, from a rabid animal constitute non-bite exposures. If the material containing the virus is dry, the virus can be considered non-infectious. Casual contact eg, petting a rabid animal and contact with blood, urine or feces (eg, guano) of a rabid animal, does not constitute an exposure and is not an indication for prophylaxis. Instances of airborne rabies have been reported rarely. Adherence to respiratory precautions will minimize the risk of airborne exposure. The only documented cases of rabies from human-to-human transmission have occurred in patients who received corneas transplanted from persons who died of rabies undiagnosed at the time of death. Stringent guidelines for acceptance of donor corneas have reduced this risk.
Bite and non-bite exposures from humans with rabies theoretically could transmit rabies, although no cases of rabies acquired this way have been documented.
Vaccination Status of Biting Animal: A properly immunized animal has only a minimal chance of developing rabies and transmitting the virus.
Presence of Rabies in Region: If adequate laboratory and field records indicate that there is no rabies infection in a domestic species within a given region, local health officials are justified in considering this in making recommendations on antirabies treatment following a bite by that particular species. Such officials should be consulted for current interpretations.
Rabies Post-Exposure Prophylaxis: The following recommendations are only a guide. In applying them, take into account the animal species involved, the circumstances of the bite or other exposure, the vaccination status of the animal, and presence of rabies in the region. Local or state public health officials should be consulted if questions arise about the need for rabies prophylaxis.
Local Treatment of Wounds: Immediate and thorough washing of all bite wounds and scratches with soap and water is perhaps the most effective measure for preventing rabies. In experimental animals, simple local wound cleansing has been shown to reduce markedly the likelihood of rabies.
Tetanus prophylaxis and measures to control bacterial infection should be given as indicated.
Active Immunization: Active immunization should be initiated as soon as possible after exposure (within 24 hrs). Many dosage schedules have been evaluated for the currently available rabies vaccines and their respective manufacturer's literature should be consulted.
Passive Immunization: A combination of active and passive immunization (vaccine and immune globulin) is considered the acceptable post-exposure prophylaxis except for those persons who have been previously immunized with rabies vaccine and who have documented adequate rabies antibody titer. These individuals should receive vaccine only. For passive immunization, rabies immune globulin (human) is preferred over antirabies serum, equine. It is recommended both for treatment of all bites by animals suspected of having rabies and for non-bite exposure inflicted by animals suspected of being rabid. Rabies immune globulin (human) should be used in conjunction with rabies vaccine and can be administered through the 7th day after the 1st dose of vaccine is given. Beyond the 7th day, rabies immune globulin (human) is not indicated since an antibody response to cell culture vaccine is presumed to have occurred.
(See table.)

Click on icon to see table/diagram/image
Dosage/Direction for Use
Recommended Dose: 20 iu/kg (0.133 mL/kg) of body weight given preferably at the time of the 1st vaccine dose. It may also be given through the 7th day after the 1st dose of vaccine is given. If anatomically feasible, up to ½ the dose of HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should be thoroughly infiltrated in the area around the wound and the rest should be administered IM in the gluteal area or lateral thigh muscle. Because of the risk of injury to the sciatic nerve, the central region of the gluteal area must be avoided; only the upper outer quadrant should be used. HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should never be administered in the same syringe or needle or in the same anatomical site as vaccine.
Contraindications
None known.
Warnings
HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) is made from human plasma. Products made from human plasma may contain infectious agents eg, viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly hepatitis C. All infections thought by a physician possibly to have been transmitted by HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should be reported by the physician or other healthcare provider to Bayer Corporation.
The physician should discuss the risks and benefits of HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) with the patient before prescribing or administering it to the patient.
HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.
The attending physician who wishes to administer HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.
As with all preparations administered by the IM route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.
Special Precautions
HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should not be administered IV because of the potential for serious reactions. Although systemic reactions to immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic symptoms.
Use in pregnancy: Pregnancy Category C: Animal reproduction studies have not been conducted with HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated). It is also not known whether it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.
Use in children: Safety and effectiveness in the pediatric population have not been established.
Use In Pregnancy & Lactation
Use in pregnancy: Pregnancy Category C: Animal reproduction studies have not been conducted with HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated). It is also not known whether it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.
Use in children: Safety and effectiveness in the pediatric population have not been established.
Adverse Reactions
Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome and anaphylactic shock have rarely been reported after IM injection, so that a causal relationship between immunoglobulin and these reactions is not clear.
Drug Interactions
Repeated doses of HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) should not be administered once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.
Other antibodies in the HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) preparation may interfere with the response to live vaccines eg, measles, mumps, polio or rubella. Therefore, immunization with live vaccines should not be given within 3 months after HyperRab (Rabies Immune Globulin-Human) (SD Viral Inactivated) administration.
Caution For Usage
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Solution that has been frozen should not be used.
Storage
Store under refrigeration (2-8°C, 36-46°F).
ATC Classification
J06BB05 - rabies immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Presentation/Packing
Inj (vial) 300 IU x 2 mL. 1500 IU x 10 mL.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in